Work

384MO Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.561

Authors: J. Robertson, Z. Shao, S. Noguchi, S. Singh, S. Subramaniam, M.J. Ellis

Institutions: University of Nottingham, Hyogo Prefectural Nishinomiya Hospital, AstraZeneca (Netherlands), AstraZeneca (India), AstraZeneca (United States)

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, Pfizer, AstraZeneca

OpenAlex ID: W4387826009

FWCI: 0.964

Cites:

Cited by: 6

Related to: 10